# InflaRx N.V. (IFRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.22, market value $327 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). InflaRx N.V. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 9597.3×**. Each dollar of revenue is priced at 9597.3×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 1.9×**. The shares trade at 1.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -8.5%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -109.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -82.6%**. Each dollar of assets produces -82.6% of profit.

## Growth
- **Revenue growth (1 yr): -82.3%**. Revenue fell 82.3% over the last year.
- **EPS growth (1 yr): 12.8%**. Earnings per share rose 12.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 4.13** (quick 4.13). Current assets cover the next year's liabilities 4.13 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. InflaRx N.V. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover InflaRx N.V.; the consensus is strong_buy, with an average price target of $7.93 (+257% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 41.4%** (YTD 119.8%, 3-mo 20.7%). The shares are up 41.4% over twelve months including dividends.
- **From 52-week high: -24.7%** (178.2% above the low). Trading 25% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.94** (volatility 102%). Beta of 1.94 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IFRX · Page: https://foliofundamentals.com/stocks/ifrx

Not investment advice.